BDBM277573 US10072026, Example 5-35::US10947254, Example 5-35::US11780852, Example 5-35

SMILES CN1CCN(Cc2ccc3c(N[C@H]4C[C@@H]5CC[C@H](C4)N5CC(F)(F)F)nc(Nc4cc(C)[nH]n4)cc3n2)CC1

InChI Key InChIKey=GNCHNEMNHRAQNW-UHFFFAOYSA-N

Data  12 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 277573   

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277573(US10072026, Example 5-35 | US10947254, Example 5-3...)
Affinity DataKi:  0.550nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2023
Entry Details
US Patent